Strategy Hints at Bitcoin Sales to Cover Dividends After Massive Q1 Loss 
Anthropic’s $1.5B AI Venture with Wall Street Firms Targets Private Equity Market 
Infineon Raises 2026 Outlook as AI Data Center Chip Demand Surges 
NAB First-Half Earnings Miss Forecasts Amid Rising Global Risks 
Meta Plans $13B AI Data Center Financing in Texas Amid Surging Big Tech Investment 
Supermicro Forecasts Strong Q4 Revenue Growth as AI Server Demand Surges 
BMW Keeps 2026 Outlook Despite 25% Profit Drop Amid Tariff Pressure 
Agentic AI Boom to Drive Massive Growth in CPU Market, UBS Says 
Middle East Conflict Impacts Australia and New Zealand Businesses 
Samsung Appoints New TV Business Head Amid Rising Competition from Chinese Rivals 
Berkshire Hathaway Meeting Sees Shift as Greg Abel Steps Into Leadership Spotlight 
Philips Reaffirms 2026 Outlook After Strong Q1 Sales and Margin Beat 
Rivian Hints at New R2 Variants as Production Ramps Up Ahead of 2027 Launch 
Strategy Reports Q1 Loss as Bitcoin Holdings Trigger $14.46 Billion Unrealized Hit 
Regis Resources and Vault Minerals to Merge in $10.7B Gold Deal 
Volvo Car Sales Drop 10% in Early 2026 Despite Growth in Electric Vehicles 
Continental AG Shares Jump After Q1 Profit Beats Expectations 
BRISBANE, Calif., May 07, 2018 -- UNITY Biotechnology, Inc. (“UNITY”) (NASDAQ:UBX) today announced the closing of the Company’s initial public offering of 5,000,000 shares of common stock at a public offering price of $17.00 per share, which does not include the exercise by the underwriters of their option to purchase up to an additional 750,000 shares of common stock. Aggregate gross proceeds to the Company were approximately $85.0 million, before underwriting discounts, commissions and estimated offering expenses. All of the shares in the offering were offered by UNITY. UNITY’s common stock is listed on The Nasdaq Global Select Market under the ticker symbol “UBX.”
Goldman Sachs & Co. LLC, Morgan Stanley and Citigroup acted as joint book-running managers for the offering. Mizuho Securities acted as a lead manager for the offering.
A registration statement relating to the shares sold in this offering was declared effective by the Securities and Exchange Commission on May 2, 2018. The offering was made only by means of a prospectus. Copies of the prospectus may be obtained from (1) Goldman Sachs & Co. LLC., Attention: Prospectus Department, 200 West Street, New York, NY 10282, Telephone: 1-866-471-2526; (2) Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, NY 10014; and (3) Citigroup Global Markets Inc., c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, Telephone: 1-800-831-9146.
This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.
About UNITY Biotechnology, Inc.
UNITY Biotechnology is developing therapeutics to extend healthspan by slowing, halting or reversing diseases of aging. UNITY's initial focus is on creating senolytic medicines to selectively eliminate senescent cells and thereby treat age-related afflictions, such as osteoarthritis, eye diseases and pulmonary diseases. UNITY's seasoned management team has experience building companies and developing medicines.
Contact: Investors Bob Goeltz [email protected] 1-650-525-4980 Media Canale Communications Jason Spark [email protected] 1-619-849-6005
